Monday, May 7, 2012

Daiichi Sankyo and Coherus BioSciences tie up for Biosimilar Development

Daiichi Sankyo and Coherus Bioscience has exclusively tied up for the development and commercialization of biosimilars for Enbrel (etanercept) and Mabthera (Rituxan)in Asian countries including Japan. Post approval Daiichi will sell the products in Japan, Taiwan and South Korea, while Coherus will retain rights for rest of the territories.

No comments:

Post a Comment